NASDAQ:IMRX

Immuneering Q2 2025 Earnings Results & Report

Immuneering logo
$3.46 -0.06 (-1.70%)
Closing price 04:00 PM Eastern
Extended Trading
$3.46 +0.00 (+0.14%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immuneering met analyst earnings expectations in its Q2 2025 results, released August 13, 2025. The company reported EPS of -$0.40 versus the -$0.40 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
12:00 AM ET

Immuneering EPS Results

Actual EPS
-$0.40
Consensus EPS
-$0.40
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Immuneering Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immuneering Q2 2025 Earnings FAQ

Immuneering (NASDAQ:IMRX) reported earnings of -$0.40 per share for Q2 2025, matching the consensus estimate of -$0.40. The report was announced on Wednesday, August 13, 2025.

Immuneering Earnings Headlines

Transcript : Immuneering Corporation - Special Call
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
See More Immuneering Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immuneering? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immuneering and other key companies, straight to your email.

About Immuneering

Immuneering (NASDAQ:IMRX) is a clinical-stage biotechnology company developing medicines for cancer. The company uses computational biology and drug-discovery approaches to study disease patterns and identify potential therapeutic targets, with a focus on the MAPK signaling pathway, which is involved in many cancers.

Its lead drug candidate, atebimetinib (IMM-1-104), is an oral investigational therapy designed to inhibit MEK proteins and disrupt MAPK signaling. Immuneering is evaluating this candidate for solid tumors, including pancreatic cancer, and is advancing additional drug candidates aimed at cancer-related pathways.

Founded in 2008, Immuneering is headquartered in Cambridge, Massachusetts. Co-founder Benjamin Zeskind serves as the company’s chief executive officer.

View Immuneering Profile